Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Relay Therapeutics Inc shares valued at $434,511 were sold by Patel Sanjiv on Nov 03 ’25. At $7.00 per share, Patel Sanjiv sold 62,073 shares. The insider’s holdings dropped to 703,215 shares worth approximately $5.72 million following the completion of this transaction.
Also, Rahmer Peter sold 21,394 shares, netting a total of over 160,455 in proceeds. Following the sale of shares at $7.50 each, the insider now holds 337,469 shares.
Before that, Rahmer Peter had sold 19,135 shares from its account. In a trade valued at $139,494, the insider traded Relay Therapeutics Inc shares for $7.29 each. Upon closing the transaction, the insider’s holdings decreased to 19,135 shares, worth approximately $2.92 million.
As published in a research note from Wells Fargo on December 12, 2025, Relay Therapeutics Inc [RLAY] has been rated up from an Equal weight to an Overweight and the price target has been revised to $13. As of April 17, 2025, Wells Fargo has initiated its “an Equal weight” rating for RLAY. Earlier on September 10, 2024, Jefferies upgraded its rating. Their new recommendation was “a Buy” for RLAY stock which previously was a “a Hold”.
Analyzing RLAY Stock Performance
On last trading session, Relay Therapeutics Inc [NASDAQ: RLAY] rose 1.25% to $8.13. The stock’s lowest price that day was $7.96, but it reached a high of $8.38 in the same session. During the last five days, there has been a surge of approximately 4.36%. Over the course of the year, Relay Therapeutics Inc shares have jumped approximately 67.98%. Shares of the company reached a 52-week high of $9.04 on 12/16/25 and a 52-week low of $1.77 on 04/07/25.
Support And Resistance Levels for Relay Therapeutics Inc (RLAY)
According to the 24-hour chart, there is a support level at 7.93, which, if violated, would cause prices to drop to 7.74. In the upper region, resistance lies at 8.35. The next price resistance is at 8.58. RSI (Relative Strength Index) is 60.02 on the 14-day chart, showing neutral technical sentiment.
Is Relay Therapeutics Inc subject to short interest?
Stocks of Relay Therapeutics Inc saw a sharp rise in short interest on 2025-11-28 jumping by 5.29 million shares to 23.16 million. Data from Yahoo Finance shows that the short interest on 2025-10-31 was 17.87 million shares. A jump of 22.84% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 10.21 of the overall float, the days-to-cover ratio (short ratio) jumped to 10.21.
Which companies own the most shares of Relay Therapeutics Inc (RLAY)?
In terms of Relay Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 13 in the next 12 months, up nearly 61.89% from the previous closing price of $8.03. Analysts anticipate Relay Therapeutics Inc stock to reach 13 by 2025, with the lowest price target being 13. In spite of this, 8 analysts ranked Relay Therapeutics Inc stock as Buy at the end of 2025. On September 10, 2024, Goldman assigned a price target of “a Buy” to the stock and resumed coverage with a $20.
